{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ma X"],"funding":["Natural Science Foundation of Zhejiang Province"],"pagination":["8937-8954"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9689525"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29(11)"],"pubmed_abstract":["<h4>Background</h4>Chemoimmunotherapy has become the first-line treatment for unresectable esophageal squamous cell carcinoma (ESCC). Still, reliable biomarkers to identify patients who could benefit from this combined therapy remain uncertain. This study focused on elucidating the predictive significance of the monocyte-to-lymphocyte ratio (MLR) and establishing the prognostic nomogram for unresectable ESCC treated with chemoimmunotherapy.<h4>Methods</h4>Data of clinical features, peripheral blood parameters, and treatment records were collected in unresectable ESCC patients who received PD-1/PD-L1 inhibitors plus chemotherapy as the first-line treatment from September 2017 to August 2021. The nomogram based on MLR and clinical parameters for predicting the overall survival (OS) was devel"],"journal":["Current oncology (Toronto, Ont.)"],"pubmed_title":["Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy."],"pmcid":["PMC9689525"],"funding_grant_id":["LQ19H160042"],"pubmed_authors":["Qian J","Zheng Y","Xu N","Ding Y","Wu L","Mao C","Wan M","Jiang H","Ma X","Chen X","Xiao C","Li N"],"additional_accession":[]},"is_claimable":false,"name":"Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy.","description":"<h4>Background</h4>Chemoimmunotherapy has become the first-line treatment for unresectable esophageal squamous cell carcinoma (ESCC). Still, reliable biomarkers to identify patients who could benefit from this combined therapy remain uncertain. This study focused on elucidating the predictive significance of the monocyte-to-lymphocyte ratio (MLR) and establishing the prognostic nomogram for unresectable ESCC treated with chemoimmunotherapy.<h4>Methods</h4>Data of clinical features, peripheral blood parameters, and treatment records were collected in unresectable ESCC patients who received PD-1/PD-L1 inhibitors plus chemotherapy as the first-line treatment from September 2017 to August 2021. The nomogram based on MLR and clinical parameters for predicting the overall survival (OS) was devel","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-19T14:44:48.273Z","creation":"2025-04-19T14:44:48.273Z"},"accession":"S-EPMC9689525","cross_references":{"pubmed":["36421355"],"doi":["10.3390/curroncol29110702"]}}